Outpatient continuous inotrope infusion as an adjunct to heart failure therapy in Duchenne muscular dystrophy

被引:12
|
作者
Cripe, Linda H. [1 ]
Barber, Brent J.
Spicer, Robert L.
Wong, Brenda L.
Weidner, Norbert
Benson, D. Woodrow
Markham, Larry W.
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Cardiol, Cincinnati, OH 45229 USA
[2] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA
[4] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA
[5] Univ Arizona, Coll Med, Div Cardiol, Tucson, AZ USA
关键词
inotropes; dobutamine; milrinone; Duchenne muscular dystrophy;
D O I
10.1016/j.nmd.2006.07.021
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We report the use of continuous intravenous inotrope infusion as a palliative management strategy for the treatment of symptomatic, refractory, end stage cardiac dysfunction in patients with Duchenne muscular dystrophy. Milrinone and/or dobutamine administered by continuous intravenous infusion provided symptomatic and objective cardiovascular improvement up to 30 months in 3 individuals with Duchenne muscular dystrophy and severe dilated cardiomyopathy. Continuous inotrope infusion should be considered a practical treatment strategy for end stage cardiac dysfunction in Duchenne muscular dystrophy patients when cardiac transplantation is not a viable option. (C) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:745 / 748
页数:4
相关论文
共 50 条
  • [41] Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy?
    Wilton, SD
    Dye, DE
    Blechynden, LM
    Laing, NG
    NEUROMUSCULAR DISORDERS, 1997, 7 (05) : 329 - 335
  • [42] Pubertal induction therapy in pediatric patients with Duchenne muscular dystrophy
    Sodero, Giorgio
    Cipolla, Clelia
    Rigante, Donato
    Arzilli, Federica
    Mercuri, Eugenio Maria
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2025,
  • [43] Next steps for the optimization of exon therapy for Duchenne muscular dystrophy
    Filonova, Galina
    Aartsma-Rus, Annemieke
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (02) : 133 - 143
  • [44] Therapy of Genetic Disorders: Novel Therapies for Duchenne Muscular Dystrophy
    Seto J.T.
    Bengtsson N.E.
    Chamberlain J.S.
    Current Pediatrics Reports, 2014, 2 (2) : 102 - 112
  • [45] Gene therapy review: Duchenne muscular dystrophy case study
    Berling, E.
    Nicolle, R.
    Laforet, P.
    Ronzitti, G.
    REVUE NEUROLOGIQUE, 2023, 179 (1-2) : 90 - 105
  • [46] Monoclonal antibodies for clinical trials of Duchenne muscular dystrophy therapy
    Le Thanh Lam
    Nguyen Thi Man
    Morris, Glenn E.
    NEUROMUSCULAR DISORDERS, 2014, 24 (03) : 195 - 200
  • [47] Effect of Ivabradine in dilated cardiomyopathy from Duchenne muscular dystrophy: A chance for slowing progression of heart failure?
    De Benedittis, Giuseppina
    Della Rosa, Giulia
    D'Ettorre, Enzo
    Piscitelli, Prisco
    Distante, Alessandro
    de Gregorio, Cesare
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 223 : 286 - 288
  • [48] Developing Advanced Chimeric Cell Therapy for Duchenne Muscular Dystrophy
    Budzynska, Katarzyna
    Bozyk, Katarzyna T.
    Jarosinska, Klaudia
    Ziemiecka, Anna
    Siemionow, Krzysztof
    Siemionow, Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (20)
  • [49] Cardiac resynchronization therapy in a young patient with Duchenne muscular dystrophy
    Kono, Tamami
    Ogimoto, Akiyoshi
    Nishimura, Kazuhisa
    Yorozuya, Toshihiro
    Okura, Takafumi
    Higaki, Jitsuo
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2015, 8 : 173 - 175
  • [50] GENE-THERAPY PROSPECTS FOR DUCHENNE MUSCULAR-DYSTROPHY
    CLEMENS, PR
    CASKEY, CT
    EUROPEAN NEUROLOGY, 1994, 34 (04) : 181 - 185